Douglas Lane & Associates LLC Buys 32,821 Shares of Bristol Myers Squibb Company $BMY

Douglas Lane & Associates LLC increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 2.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,572,246 shares of the biopharmaceutical company’s stock after purchasing an additional 32,821 shares during the period. Bristol Myers Squibb makes up 1.2% of Douglas Lane & Associates LLC’s portfolio, making the stock its 22nd biggest position. Douglas Lane & Associates LLC owned approximately 0.08% of Bristol Myers Squibb worth $84,807,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of BMY. Brighton Jones LLC lifted its holdings in shares of Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC increased its position in shares of Bristol Myers Squibb by 59.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 2,786 shares during the last quarter. United Bank increased its position in shares of Bristol Myers Squibb by 15.0% during the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after purchasing an additional 3,277 shares during the last quarter. Marshall Wace LLP bought a new position in Bristol Myers Squibb during the second quarter worth about $221,000. Finally, Baker Avenue Asset Management LP increased its holdings in shares of Bristol Myers Squibb by 35.0% during the 2nd quarter. Baker Avenue Asset Management LP now owns 4,752 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 1,232 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Cobenfy shows commercial traction — 2025 sales of roughly $155M, outpacing peers and supporting upside from label expansion and new indications, which strengthens BMY’s growth outlook. Does Cobenfy Have the Potential to Become a Top Drug for BMY?
• Positive Sentiment: New Oxford BioTherapeutics collaboration to discover next‑gen T‑cell engagers for solid tumors — deal includes upfront, milestones and royalties and validates BMS’s oncology partnering strategy. This could expand pipeline optionality and future revenue streams. Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours
• Positive Sentiment: Guggenheim reaffirmed a “buy” and a $72 price target, supporting optimism among some sell‑side investors about longer-term upside. Guggenheim Reaffirms Buy on BMY
• Neutral Sentiment: Bank of America trimmed its price target slightly (from $68 to $67) but kept a “buy” rating — modest tweak that doesn’t change the positive rating but narrows near‑term upside. BofA Price Target Change
• Neutral Sentiment: BofA note that biopharma names are largely exempt from proposed pharma tariffs — reduces a macro policy risk for large-cap drugmakers like BMY. Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says
• Negative Sentiment: Q1 earnings risk — Street previews point to a potential double‑digit drop in Q1 EPS, a near‑term catalyst that could pressure the stock if results miss expectations. Bristol-Myers Squibb Earnings Preview: What to Expect
• Negative Sentiment: Cantor Fitzgerald raised its target from $45 to $54 but reiterated a Neutral rating and flagged a weak Q1 catalyst — the note highlights limited near‑term upside. Cantor Fitzgerald Lifts Bristol Myers (BMY) Price Target but Flags Weak Q1 Catalyst

Analysts Set New Price Targets

BMY has been the topic of a number of recent analyst reports. Leerink Partners boosted their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Guggenheim reissued a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday. HSBC boosted their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Piper Sandler reissued an “overweight” rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Finally, Wells Fargo & Company reissued an “outperform” rating and set a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Hold” and an average target price of $61.71.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY opened at $59.48 on Friday. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The stock’s fifty day moving average price is $59.70 and its two-hundred day moving average price is $53.02. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The firm has a market cap of $121.45 billion, a price-to-earnings ratio of 17.24, a P/E/G ratio of 0.17 and a beta of 0.27.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same period in the prior year, the company earned $1.67 earnings per share. The business’s quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 73.04%.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This represents a 15.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.09% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.